Amgen executives detailed their alleged Aranesp "overfill" kickback scheme in a set of PowerPoint slides and Excel spreadsheets, according to a lawsuit filed by the New York State Attorney General.

Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel found. Outside advisors to the Food and Drug Administration said the ...

The study showed patients treated with Aranesp had a reduction in the number of red blood cell transfusions Amgen announced positive results from the Phase 3 ARCADE study evaluating Aranesp ...

Amgen is the subject of the FDA’s latest untitled letters. The regulator’s Office of Prescription Drug Promotion (OPDP) knocked the company for a mailer promoting it its chronic kidney disease anemia ...

NEW YORK, Feb 16 (Reuters) - Amgen Inc.'s multibillion-dollar anemia drug Aranesp is facing further safety concerns after a medical newsletter reported on Friday that a Danish study of the drug in ...

ORLANDO, Fla., (May 15, 2005) – Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that new interim data from a single-arm, open label study of 1,225 cancer patients ...

Please provide your email address to receive an email when new articles are posted on . Aranesp use has increased from 2.5% in January 2014 to 21% in December 2015, while epoetin alfa use has fallen ...

THOUSAND OAKS, Calif., September 7, 2006 -- Amgen (NASDAQ: AMGN) today announced the launch of the Aranesp® (darbepoetin alfa) prefilled SureClick TM autoinjector for patients with ...

Biotechnology giant Amgen today pleaded guilty in federal court to a misdemeanor charge of misbranding Aranesp (darbepoetin alfa), its highly successful anemia drug. The government accused Amgen of ...

LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...

Amgen has dodged a potential Aranesp bullet. A new study dubbed "TREAT" showed that while the anemia drug didn't improve the heart health of patients with chronic kidney disease, it didn't hurt, ...

Biotech giant Amgen Inc. pleaded guilty in federal court to improper marketing of its anemia drug Aranesp and has agreed to pay $762 million in criminal fines and civil settlements to resolve ...